Examkin

Question

Difficulty: MediumBias, Confounding, and Validity

A clinical research team conducts a prospective cohort study to evaluate the safety of a newly approved anti-seizure medication (ASM) for refractory focal epilepsy. The primary outcome of interest is the incidence of significant cognitive decline over a 2-year follow-up period, compared to standard ASM therapy. The initial unadjusted analysis yields a relative risk (RR) of 1.50 (95% CI: 1.20 - 1.85), suggesting that the new ASM increases the risk of cognitive decline.

During a review of baseline characteristics, the investigators note that patients prescribed the new ASM generally had a much longer duration of epilepsy prior to study enrollment. To investigate this, they perform a stratified analysis based on epilepsy duration:

- Duration <10< 10 years: RR = 1.031.03 (95% CI: 0.85 - 1.25)
- Duration ≥10\geq 10 years: RR = 1.011.01 (95% CI: 0.80 - 1.20)

Based on the statistical findings from the stratified analysis, which of the following statements most accurately characterizes the epidemiological role of epilepsy duration in this research?

  1. A
    It biologically interacts with the novel medication to selectively amplify the risk of cognitive decline in a specific patient population.
  2. B
    It is a downstream pathological consequence of the novel medication that subsequently leads to the cognitive outcome.
  3. C
    It introduces a systematic flaw in how the presence of cognitive decline was detected by the study investigators.
  4. It represents an extraneous factor whose unequal baseline distribution between the treatment groups distorts the apparent overall association.Answer
  5. E
    It causes non-random dropout of participants during the 2-year period, creating an artificial association in the remaining study population.

Answer

The epidemiological role described is an extraneous factor whose unequal baseline distribution between the treatment groups distorts the apparent overall association (confounding).
The correct answer accurately defines a confounding variable without using the explicit term. The key finding in the study is that the crude relative risk (1.501.50) indicated a strong association, but upon stratification by epilepsy duration, the relative risk in both subgroups fell to approximately 1.01.0 (no association). This statistical pattern indicates that the original association was artificial and driven entirely by the unequal baseline distribution of epilepsy duration between the two treatment groups. In epidemiology, when an apparent association disappears upon stratification across all subgroups, the stratifying variable is a confounder.

Step-by-Step Solution

1
Analyze the crude relative risk (RR).
The unadjusted RR is 1.501.50, indicating an apparent increased risk of cognitive decline with the new medication.
Establishing the baseline finding is necessary to compare with the stratified results.
2
Evaluate the results of the stratified analysis.
When stratified by epilepsy duration, the RR in both the <10< 10 years and ≥10\geq 10 years subgroups drops to approximately 1.01.0 (null association).
Stratification separates the study population by a potential third variable to observe its specific effects.
3
Interpret the change between crude and stratified RRs.
Because the association disappears in all strata, the initial association was completely driven by the unequal distribution of epilepsy duration between the groups.
A significant crude association that becomes null upon stratification is the pathognomonic statistical signature of confounding.

Key Concept

Confounding occurs when an extraneous variable is associated with both the exposure and the outcome, distorting the apparent relationship. Stratified analysis identifies confounding when stratum-specific measures of association become similar to each other but differ significantly from the crude measure.
Rate this question

Topics

Bias, Confounding, and Validity

More questions from this topic